Form 8-K · Current report
Labcorp 8-K, filed Oct 28, 2026
- Filed
- CIK
- 0000920148
- Accession no.
- 0000920148-26-000213
Summary
Labcorp reported third-quarter 2026 revenue of $3.81 billion, up 6.9%, and adjusted EPS of $4.78, up 14.5%, and raised its full-year 2026 revenue growth and adjusted EPS guidance. CEO Adam Schechter said the quarter reflected specialty testing launches and acquisitions across its Diagnostics and Biopharma Laboratory Services businesses.
Key points
- Labcorp received FDA approval of PGDx elio tissue complete CDx as a companion diagnostic to help identify patients with advanced melanoma.
- Labcorp announced or closed four transactions during the quarter and, after quarter end, signed agreements to acquire select BioReference Health laboratory assets, Myriad Genetics' Prenatal Health business, and Millennium Health.
- Labcorp launched the FDA-cleared Elecsys pTau-217 blood test for Alzheimer's disease and a hepatitis D reflex testing option.
- Labcorp declared a quarterly cash dividend of $0.72 per share and has $1.4 billion remaining under its share repurchase authorization.
Written by an AI model from the filing text. It can be incomplete or wrong; the filing on SEC.gov is the record.
Items reported
- 2.02Results of Operations and Financial Condition
- 9.01Financial Statements and Exhibits
From the filing
Item 2.02. Results of Operations and Financial Condition. Item 9.01. Financial Statements and Exhibits. Exhibit Exhibit Name Exhibit 99.1 Press release dated October 28, 2026 issued by Labcorp Holdings Inc., announcing its results for the quarter ended September 30, 2026. Exhibit 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) Exhibit 99.1: EX-99.1 2 form8-kexhibit9913q26.htm EX-99.1 FOR IMMEDIATE RELEASE Contact: Nickolo Russo - Investors Racquel White - Media [email protected] [email protected] Labcorp Reports Strong 2026 Third Quarter Results; …
An excerpt of the text as filed with the SEC, cut for length.
Readster writes AI-generated summaries of public filings for research purposes only. Summaries can be incomplete or wrong — check the original filing on SEC.gov before relying on it. Nothing here is investment, legal or medical advice.